JP2012508172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508172A5 JP2012508172A5 JP2011534887A JP2011534887A JP2012508172A5 JP 2012508172 A5 JP2012508172 A5 JP 2012508172A5 JP 2011534887 A JP2011534887 A JP 2011534887A JP 2011534887 A JP2011534887 A JP 2011534887A JP 2012508172 A5 JP2012508172 A5 JP 2012508172A5
- Authority
- JP
- Japan
- Prior art keywords
- factor according
- coagulation factor
- starch
- amino acid
- coagulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 9
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 9
- 239000003114 blood coagulation factor Substances 0.000 claims 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 4
- 229920000249 biocompatible polymer Polymers 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 229920000936 Agarose Polymers 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 229920002527 Glycogen Polymers 0.000 claims 1
- 229920002907 Guar gum Polymers 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims 1
- 229920001202 Inulin Polymers 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 239000004373 Pullulan Substances 0.000 claims 1
- 229920001218 Pullulan Polymers 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000008065 acid anhydrides Chemical class 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 125000004057 biotinyl group Chemical class [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 239000001341 hydroxy propyl starch Substances 0.000 claims 1
- 229940050526 hydroxyethylstarch Drugs 0.000 claims 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
- 229940029339 inulin Drugs 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 229960000292 pectin Drugs 0.000 claims 1
- 229920003175 pectinic acid Polymers 0.000 claims 1
- 229920000765 poly(2-oxazolines) Polymers 0.000 claims 1
- 229920005646 polycarboxylate Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 235000019423 pullulan Nutrition 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11080908P | 2008-11-03 | 2008-11-03 | |
| US61/110,809 | 2008-11-03 | ||
| PCT/US2009/063151 WO2010062768A1 (en) | 2008-11-03 | 2009-11-03 | Method for the treatment of hemophilia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012508172A JP2012508172A (ja) | 2012-04-05 |
| JP2012508172A5 true JP2012508172A5 (enExample) | 2012-12-20 |
Family
ID=42225997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534887A Pending JP2012508172A (ja) | 2008-11-03 | 2009-11-03 | 血友病の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120027743A1 (enExample) |
| EP (1) | EP2352515A4 (enExample) |
| JP (1) | JP2012508172A (enExample) |
| KR (1) | KR20110093775A (enExample) |
| CN (1) | CN102202684A (enExample) |
| CA (1) | CA2740793A1 (enExample) |
| WO (1) | WO2010062768A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0720282B8 (pt) | 2006-12-15 | 2021-05-25 | Baxalta GmbH | construção proteica, composição farmacêutica, e, kit |
| AR069989A1 (es) | 2007-12-28 | 2010-03-03 | Baxter Int | Formulaciones de vwf recombinantes |
| US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| AU2009307648C1 (en) | 2008-10-21 | 2016-12-08 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| NZ606427A (en) | 2009-02-03 | 2014-10-31 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
| EP3081233B1 (en) | 2009-07-27 | 2020-12-23 | Baxalta GmbH | Glycopolysialylation of proteins other than blood coagulation proteins |
| EP2459224B1 (en) | 2009-07-27 | 2016-06-01 | Baxalta GmbH | Blood coagulation protein conjugates |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
| EP2470670A4 (en) | 2009-08-24 | 2013-07-10 | Amunix Operating Inc | COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| HUE049352T2 (hu) | 2010-12-22 | 2020-09-28 | Baxalta GmbH | Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására |
| ES2771208T3 (es) | 2012-02-15 | 2020-07-06 | Bioverativ Therapeutics Inc | Composiciones de factor VIII y métodos de preparación y uso de las mismas |
| BR112014019901A8 (pt) | 2012-02-15 | 2018-01-02 | Biogen Idec Inc | Proteínas de fator viii recombinante |
| US20150045303A1 (en) | 2012-04-24 | 2015-02-12 | Novo Nordisk A/S | Pharmaceutical Composition Suitable for Treatment of Haemophilia |
| EP2841451A1 (en) | 2012-04-24 | 2015-03-04 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
| EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
| BR112018002150A2 (pt) | 2015-08-03 | 2018-09-18 | Bioverativ Therapeutics Inc | proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas |
| US12161696B2 (en) | 2016-12-02 | 2024-12-10 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| DK3793588T3 (da) | 2018-05-18 | 2025-06-16 | Bioverativ Therapeutics Inc | Fremgangsmåder til behandling af hæmofili a |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| IL113010A0 (en) * | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US8465468B1 (en) * | 2000-06-29 | 2013-06-18 | Becton, Dickinson And Company | Intradermal delivery of substances |
| CN1767857A (zh) * | 2003-02-26 | 2006-05-03 | 尼克塔治疗亚拉巴马公司 | 聚合物－因子ⅷ部分共轭物 |
| CN105753968A (zh) * | 2004-11-12 | 2016-07-13 | 拜尔健康护理有限责任公司 | Fviii的位点定向修饰 |
| JP2008534559A (ja) * | 2005-04-01 | 2008-08-28 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 血液凝固ｆｖｉｉｉ類似体 |
| EP2099475B1 (en) * | 2007-01-03 | 2016-08-24 | Novo Nordisk Health Care AG | Subcutaneous administration of coagulation factor viia-related polypeptides |
| WO2008119815A1 (en) * | 2007-04-02 | 2008-10-09 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor ix |
-
2009
- 2009-11-03 CN CN2009801426047A patent/CN102202684A/zh active Pending
- 2009-11-03 EP EP09829685A patent/EP2352515A4/en not_active Withdrawn
- 2009-11-03 KR KR1020117010062A patent/KR20110093775A/ko not_active Withdrawn
- 2009-11-03 WO PCT/US2009/063151 patent/WO2010062768A1/en not_active Ceased
- 2009-11-03 US US13/127,461 patent/US20120027743A1/en not_active Abandoned
- 2009-11-03 CA CA2740793A patent/CA2740793A1/en not_active Abandoned
- 2009-11-03 JP JP2011534887A patent/JP2012508172A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012508172A5 (enExample) | ||
| Yuan et al. | Progress and prospects of polysaccharide-based nanocarriers for oral delivery of proteins/peptides | |
| JP2013519636A5 (enExample) | ||
| Chang et al. | Amphiphilic hydrogels for biomedical applications | |
| Kadajji et al. | Water soluble polymers for pharmaceutical applications | |
| Lee et al. | PLA micro-and nano-particles | |
| Nita et al. | New trends in bio-based aerogels | |
| Celebioglu et al. | Fast dissolving oral drug delivery system based on electrospun nanofibrous webs of cyclodextrin/ibuprofen inclusion complex nanofibers | |
| JP2018040002A5 (enExample) | ||
| Liu et al. | Cyclodextrin-containing hydrogels: a review of preparation method, drug delivery, and degradation behavior | |
| Moscovici | Present and future medical applications of microbial exopolysaccharides | |
| JP2018535704A5 (enExample) | ||
| JP2008516735A5 (enExample) | ||
| Dumitriu | Polysaccharides as biomaterials | |
| Hardy et al. | β-Cyclodextrin-functionalized chitosan/alginate compact polyelectrolyte complexes (CoPECs) as functional biomaterials with anti-inflammatory properties | |
| JP2016073641A5 (enExample) | ||
| JP2012506904A5 (enExample) | ||
| JP2015516240A5 (enExample) | ||
| Mndlovu et al. | Bioplatform fabrication approaches affecting chitosan-based interpolymer complex properties and performance as wound dressings | |
| JP2010537989A5 (enExample) | ||
| CA2389251A1 (en) | Swelling and deswelling polymer blends | |
| JP2006522829A5 (enExample) | ||
| Wahab et al. | Polysaccharides as composite biomaterials | |
| Sirisha et al. | Polysaccharide-based nanoparticles as drug delivery systems | |
| JP2011513393A5 (enExample) |